Virtual Presentation
New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors
Source: New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors
New Classes of Antiretrovirals: The Potential Clinical Role of Integrase Inhibitors and Entry Inhibitors
  
- Eric S. Daar, MD
- Joseph J. Eron, Jr., MD
- Daniel R. Kuritzkes, MD
|
  
- John A. Bartlett, MD
- Joseph Cofrancesco, Jr., MD, MPH, FACP
- Edwin DeJesus, MD, FACP, AAHIVS
|
  
- W. David Hardy, MD
- Richard Haubrich, MD
- William A. O'Brien, MD, MS
|
  
- Bruce Polsky, MD
- Kimberly Y. Smith, MD, MPH
- Kathleen E. Squires, MD
|
  
- Pablo Tebas, MD
- Benjamin Young, MD, PhD
- Andrew R. Zolopa, MD
|
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the need for novel antiretroviral agents
- Describe recent data on agents in novel classes
- Identify the clinical settings in which novel antiretroviral agents may find application
CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|